CONVIDECIA, a vaccine produced by Chinese manufacturer CanSino Biologics, showed a 95.35-percent efficacy rate in preventing intensive care unit admission 28 days after one shot in administrated to a person, a study conducted in Chile found.
The efficacy was similar to the 96.56-percent rate for two doses of Pfizer's mRNA vaccine after 14 days and higher than the 86.88-percent rate of two shots of inactivated vaccines after two weeks, according to a statement released by the company on Monday.
Already have an active account? Log in here.
Continue reading with one of these options:
Continue reading with one of these options:
Premium + Digital Edition
Ad-free access
P 80 per month
(billed annually at P 960)
- Unlimited ad-free access to website articles
- Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)
TRY FREE FOR 14 DAYS
See details
See details
If you have an active account, log in
here
.